The FDA has expanded approval of Amgen’s Repatha® (evolocumab) to include adults at risk for major cardiovascular events from uncontrolled LDL-C, even without a prior diagnosis of cardiovascular disease.
The expansion is especially meaningful for people with diabetes, who face a higher likelihood of diabetic dyslipidemia—low HDL (‘good’ cholesterol), high triglycerides, and elevated LDL (‘bad’ cholesterol)—a combination that accelerates cardiovascular risk. Having another treatment option for lowering LDL-C could help fill a critical gap for patients who remain at risk despite best efforts with diet, exercise, and statins.
Earlier access to Repatha gives clinicians another tool to close gaps in cholesterol control and offers at-risk patients, including many with diabetes, a new and effective option to help prevent heart attack or stroke.
Sources
